Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedJul 11, 2026
DataAggregated Company Financials
Companies554
  • 7D-2.4%
  • 3M8.9%
  • 1Y35.9%
  • YTD11.8%

Over the last 7 days, the Biotech industry has dropped 2.4%, driven by a pullback from AbbVie of 5.0%. Meanwhile, BridgeBio Pharma actually outperformed within the industry, gaining 11% in the last week. In the past year, the industry has gained 36%. As for the next few years, earnings are expected to grow by 25% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 11 Jul 2026US$1.5tUS$169.9b-US$12,256,719,187.0617.4x-119x8.6x
Mon, 08 Jun 2026US$1.3tUS$170.0b-US$12,160,280,783.8216.6x-104.3x7.5x
Wed, 06 May 2026US$1.3tUS$167.8b-US$11,985,692,255.0217.6x-106.9x7.6x
Fri, 03 Apr 2026US$1.3tUS$166.1b-US$11,566,538,901.6615.2x-111.7x7.8x
Sun, 01 Mar 2026US$1.4tUS$169.4b-US$12,634,834,488.1021.8x-106.9x8x
Tue, 27 Jan 2026US$1.3tUS$163.6b-US$15,179,170,056.4920.1x-83.7x7.8x
Thu, 25 Dec 2025US$1.3tUS$163.6b-US$15,776,968,733.0722.2x-79.3x7.7x
Sat, 22 Nov 2025US$1.2tUS$163.8b-US$16,230,986,627.5318.2x-73.1x7.2x
Mon, 20 Oct 2025US$1.2tUS$163.4b-US$18,206,489,780.5816.4x-64.1x7.1x
Wed, 17 Sep 2025US$1.1tUS$163.5b-US$18,384,185,199.8816.2x-58x6.5x
Fri, 15 Aug 2025US$1.1tUS$163.7b-US$18,854,545,748.5115.4x-56.4x6.5x
Sun, 13 Jul 2025US$973.9bUS$155.8b-US$23,414,756,764.1818.1x-41.6x6.3x
Tue, 10 Jun 2025US$952.0bUS$155.9b-US$23,940,289,678.7417x-39.8x6.1x
Thu, 08 May 2025US$890.3bUS$155.1b-US$25,574,283,733.6818.6x-34.8x5.7x
Sat, 05 Apr 2025US$774.2bUS$118.6b-US$37,107,737,767.7320.1x-20.9x6.5x
Mon, 03 Mar 2025US$850.8bUS$118.9b-US$37,265,127,499.9717x-22.8x7.2x
Wed, 29 Jan 2025US$991.6bUS$149.5b-US$26,314,079,099.9617.5x-37.7x6.6x
Fri, 27 Dec 2024US$990.4bUS$149.9b-US$26,370,197,964.7716.1x-37.6x6.6x
Sun, 24 Nov 2024US$1.0tUS$150.0b-US$26,558,578,256.4416.6x-38.3x6.8x
Tue, 22 Oct 2024US$908.0bUS$113.1b-US$36,019,658,167.4321.3x-25.2x8x
Thu, 19 Sep 2024US$925.6bUS$113.2b-US$35,972,157,840.1222.6x-25.7x8.2x
Sat, 17 Aug 2024US$882.4bUS$113.2b-US$35,765,976,434.6822.3x-24.7x7.8x
Mon, 15 Jul 2024US$1.2tUS$164.5b-US$28,105,214,748.9029.4x-42.5x7.3x
Wed, 12 Jun 2024US$1.2tUS$164.5b-US$26,795,949,828.0928.2x-43.3x7.1x
Fri, 10 May 2024US$1.1tUS$164.8b-US$26,733,495,747.4523.2x-41.9x6.8x
Sun, 07 Apr 2024US$1.1tUS$164.4b-US$23,431,530,428.0321.3x-48.2x6.9x
Tue, 05 Mar 2024US$1.2tUS$167.9b-US$21,298,840,556.0315.9x-56x7.1x
Thu, 01 Feb 2024US$1.4tUS$204.7b-US$22,672,999,235.0017.8x-63.6x7x
Sat, 30 Dec 2023US$1.4tUS$204.9b-US$22,199,644,413.0019.8x-62.9x6.8x
Mon, 27 Nov 2023US$1.2tUS$204.8b-US$22,013,452,568.0018.6x-55.7x6x
Wed, 25 Oct 2023US$1.2tUS$207.5b-US$13,040,888,319.0016.2x-93x5.8x
Fri, 22 Sep 2023US$1.3tUS$207.5b-US$12,875,537,971.0017.1x-98.4x6.1x
Sun, 20 Aug 2023US$1.3tUS$207.6b-US$12,372,676,716.0017.6x-102.2x6.1x
Tue, 18 Jul 2023US$1.1tUS$186.7b-US$15,958,556,257.0012.9x-71.1x6.1x
Price to Earnings Ratio

-71.1x


Total Market Cap: US$1.1tTotal Earnings: -US$15,958,556,257.00Total Revenue: US$186.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -59.4x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 8.6x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 3.1% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.74%
Healthcare-1.52%
Biotech-2.37%
Biotech-2.37%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BBIO BridgeBio PharmaUS$85.8911.3%
+US$1.7b		84.8%PS29x
REGN Regeneron PharmaceuticalsUS$664.521.6%
+US$1.0b		17.0%PE15.3x
SYRE Spyre TherapeuticsUS$97.7412.8%
+US$964.8m		522.9%PB16.5x
INSM InsmedUS$115.613.6%
+US$869.2m		17.8%PS30.6x
XENE Xenon PharmaceuticalsUS$68.9213.1%
+US$769.5m		114.0%PB5x

Latest News

GILD
US$129.83
Gilead Sciences
7D
-1.1%
1Y
18.4%
BBIO
US$85.89
BridgeBio Pharma
7D
11.3%
1Y
84.8%
IONS
US$58.25
Ionis Pharmaceuticals
7D
-28.8%
1Y
39.6%
MRNA
US$68.27
Moderna
7D
-14.4%
1Y
102.9%
XENE
US$68.92
Xenon Pharmaceuticals
7D
13.1%
1Y
114.0%
Narrative Update • Jul 10

XENE: Epilepsy Trial Progress Will Define Edge Versus Slower Kv7 Rival

Analysts have lifted their fair value estimate for Xenon Pharmaceuticals from about $55.40 to about $80.56, reflecting updated models that incorporate revised assumptions for long term revenue potential, profit margins, and future P/E multiples in light of recent Street research and competitive positioning versus Biohaven. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights a mix of optimism on the epilepsy opportunity and caution around execution and competitive risk, particularly in comparison with Biohaven.
ABBV
US$248.08
AbbVie
7D
-5.0%
1Y
28.9%
Narrative Update • Jul 10

ABBV: Future Returns Will Depend On Apogee Deal And Broader Immunology Expansion

AbbVie’s refreshed analyst price target framework edges higher to about $259 from roughly $254, with analysts pointing to updated Q2 models, recent target hikes across several firms, and added confidence around the Apogee acquisition’s immunology and respiratory potential as key supports for the revision. Analyst Commentary Recent research on AbbVie centers on two main themes, the refreshed Q2 earnings models and the planned Apogee Therapeutics acquisition.
AMGN
US$363.39
Amgen
7D
-2.9%
1Y
23.1%
Narrative Update • Jul 10

AMGN: IRS Dispute And Regulatory Setbacks Will Pressure Future Returns

Amgen's updated analyst price target now reflects a fair value estimate of $252.61. Analysts point to refined revenue and margin assumptions, a slightly higher discount rate, and sector-level research that highlights both supportive biotech conditions and company-specific model updates following recent earnings and regulatory disclosures.
FBRX
US$43.92
Forte Biosciences
7D
109.9%
1Y
316.3%
INSM
US$115.61
Insmed
7D
3.6%
1Y
17.8%
ALNY
US$298.76
Alnylam Pharmaceuticals
7D
-4.5%
1Y
-5.1%
Seeking Alpha • Jul 09

Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook

Summary Alnylam Pharmaceuticals stands to benefit from the unexpected Phase III failure of Ionis/AstraZeneca’s eplontersen, as it removes a key competitor in the ATTR-CM space. ALNY’s Amvuttra is positioned to capture potential billions in peak revenue previously modeled for Wainua, though better stabilizer performance may temper first-line and long-term combo usage. One less competitor in the ATTR-CM space is a positive, but the CARDIO-TTRansform could point to some elevated risks for ALNY's own Phase III TRITON-CM study of nucresiran. Upcoming Phase I/II readouts for ALN-6400, ALN-HTT02, and ALN-2232 could drive renewed Street enthusiasm and add 5% or more to fair value estimates. I raise my fair value estimate for ALNY from $450 to nearly $490, maintaining a bullish stance despite ongoing biotech risks and competitive threats. Read the full article on Seeking Alpha
VRTX
US$485.39
Vertex Pharmaceuticals
7D
-8.1%
1Y
3.5%
Narrative Update • Jul 08

VRTX: Rich Crinetics Deal Will Weigh On Future Risk Reward Profile

Vertex Pharmaceuticals' fair value estimate has been adjusted higher by about $9.69 to $423.75 as analysts factor in updated assumptions on revenue growth, margins, and future P/E following the Crinetics acquisition and a series of upward price target revisions, including recent moves to $570 at RBC Capital and $350 at Baird. Analyst Commentary Recent research on Vertex Pharmaceuticals clusters around the planned Crinetics acquisition and how it reshapes the company’s pipeline mix, capital deployment, and earnings profile.
REGN
US$664.52
Regeneron Pharmaceuticals
7D
1.6%
1Y
17.0%
ROIV
US$35.97
Roivant Sciences
7D
2.4%
1Y
216.6%
BIIB
US$199.15
Biogen
7D
-7.9%
1Y
48.4%
Narrative Update • Jul 08

BIIB: Alzheimer’s Trial Uncertainty Will Likely Undermine Recent Acquisition Optimism

Biogen's analyst fair value estimate has been raised from $150.59 to $162.20 as analysts factor in higher price targets, a slightly lower discount rate, and more constructive views on the pipeline and the potential for a stabilizing core business. Analyst Commentary Recent Street research on Biogen shows a mix of optimism around the pipeline and caution around execution, valuation, and the balance of risks.
SYRE
US$97.74
Spyre Therapeutics
7D
12.8%
1Y
522.9%
TRAX
US$36.24
First Tracks Biotherapeutics
7D
87.8%
1Y
n/a